Raha-Chowdhury et al., 2019 - Google Patents
Choroid plexus acts as gatekeeper for TREM2, abnormal accumulation of ApoE, and fibrillary tau in Alzheimer's disease and in Down syndrome dementiaRaha-Chowdhury et al., 2019
View HTML- Document ID
- 13570157512317599607
- Author
- Raha-Chowdhury R
- Henderson J
- Raha A
- Vuono R
- Bickerton A
- Jones E
- Fincham R
- Allinson K
- Holland A
- Zaman S
- Publication year
- Publication venue
- Journal of Alzheimer's disease
External Links
Snippet
Background: Genetic factors that influence Alzheimer's disease (AD) risk include mutations in TREM2 and allelic variants of Apolipoprotein E, influencing AD pathology in the general population and in Down syndrome (DS). Evidence shows that dysfunction of the choroid …
- 201000010374 Down syndrome 0 title abstract description 208
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raha-Chowdhury et al. | Choroid plexus acts as gatekeeper for TREM2, abnormal accumulation of ApoE, and fibrillary tau in Alzheimer’s disease and in Down syndrome dementia | |
| Button et al. | HDL from an Alzheimer's disease perspective | |
| Hoogmartens et al. | Insight into the genetic etiology of Alzheimer's disease: A comprehensive review of the role of rare variants | |
| Area-Gomez et al. | A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease | |
| Liao et al. | Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation | |
| Karch et al. | Alzheimer’s disease risk genes and mechanisms of disease pathogenesis | |
| Montagne et al. | Alzheimer’s disease: a matter of blood–brain barrier dysfunction? | |
| Liu et al. | APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia | |
| Yeh et al. | TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia | |
| Saunders | Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses | |
| Cohen et al. | Rapidly progressive Alzheimer’s disease features distinct structures of amyloid-β | |
| Shao et al. | Genetics of Alzheimer’s disease: From pathogenesis to clinical usage | |
| Tomiyama et al. | A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia | |
| Laws et al. | Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription | |
| Holtzman | In vivo effects of ApoE and clusterin on amyloid-β metabolism and neuropathology | |
| Liu et al. | Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease | |
| Zhu et al. | State of play in Alzheimer’s disease genetics | |
| Thygesen et al. | Diverse protein profiles in CNS myeloid cells and CNS tissue from lipopolysaccharide-and vehicle-injected APPSWE/PS1ΔE9 transgenic mice implicate cathepsin Z in Alzheimer’s disease | |
| Xiao et al. | Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer’s disease | |
| Camacho et al. | Brain ApoA-I, ApoJ and ApoE immunodetection in cerebral amyloid angiopathy | |
| Merched et al. | Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease | |
| Johansson et al. | Reduced cerebrospinal fluid concentration of apolipoprotein AI in patients with Alzheimer’s disease | |
| Endres | Apolipoprotein A1, the neglected relative of Apolipoprotein E and its potential role in Alzheimer’s disease | |
| Giri et al. | Unraveling the genes implicated in Alzheimer's disease | |
| Islam et al. | Presenilin is essential for ApoE secretion, a novel role of Presenilin involved in Alzheimer's disease pathogenesis |